Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature

被引:9
|
作者
Li, Ye [1 ]
Lv, Xinna [1 ]
Wang, Bing [2 ]
Xu, Zexuan [1 ]
Wang, Yichuan [2 ]
Sun, Mengyan [1 ]
Hou, Dailun [1 ]
机构
[1] Capital Med Univ, Beijing Chest Hosp, Dept Radiol, Beijing, Peoples R China
[2] Beijing TB & Thorac Tumor Res Inst, Dept Radiol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Radiomics; Magnetic Resonance Imaging; EGFR; T790M; Brain Metastases;
D O I
10.1016/j.acra.2022.12.030
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: Timely identifying T790M mutation for non-small cell lung cancer (NSCLC) patients with brain metastases (BM) is essential to adjust targeted treatment strategies. To develop and validate radiomics models based on multisequence MRI for differenti-ating patients with T790M resistance from no T790M mutation in BM and explore the optimal sequence for prediction. Materials and Methods: This retrospective study enrolled 233 patients with proven of BM in NSCLC which included 95 with T790M and 138 without T790M from two hospitals as the training cohort and testing cohort separately. Radiomics features extracted from T2WI, T2 fluid-attenuated inversion recovery (T2-FLAIR), diffusion weighted imaging (DWI) and contrast-enhanced T1-weighted imaging (T1-CE) sequence respectively. The most predictable features were selected based on the maximal information coefficient and Boruta method. Then four radiomics models were built to characterize T790M mutation by random forest classifier. ROC curves, F1 score and DCA curves were constructed to validate the capability and verify the performance of four models.Results: The DWI model showed best performance with AUC and F1 score of 0.886 and 0.789 in the training cohort, 0.850 and 0.743 in the testing cohort. DCA curves also showed higher overall net benefit from the DWI model than from the remaining three models in the testing cohort. Other three models also had some classification power whether in the training or testing cohort, especially T2-FLAIR model.Conclusion: Multisequence MRI-based radiomics has potential to predict the emergence of EGFR T790M resistance mutations especially the radiomics signature based on DWI sequence.
引用
下载
收藏
页码:1887 / 1895
页数:9
相关论文
共 50 条
  • [21] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
    Zhao, Sha
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Jia, Yijun
    Shi, Jinpeng
    He, Yayi
    Li, Jiayu
    Zhou, Fei
    Gao, Guanghui
    Li, Wei
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2019, 128 : 33 - 39
  • [22] Intracranial Activity of Osimertinib in Naive EGFRm T790M(-) And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
    Peled, N.
    Nechushtan, H.
    Ilouze, M.
    Dudnik, E.
    Inbar, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2223 - S2223
  • [23] A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA
    Kimura, Hideharu
    Nishikawa, Shingo
    Koba, Hayato
    Yoneda, Taro
    Sone, Takashi
    Kasahara, Kazuo
    CIRCULATING NUCLEIC ACIDS IN SERUM AND PLASMA - CNAPS IX, 2016, 924 : 171 - 174
  • [24] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
    Yang, Zhengquan
    Li, Jialu
    Hu, Yujie
    Chen, Meihua
    Peng, Danli
    Zong, Dan
    Shang, Qingjuan
    Tao, Lianqin
    Zhao, Yanling
    Ni, Yiyun
    Ye, Jinyan
    Xie, Yupeng
    Yang, Li
    Lin, Quan
    Cai, Chang
    Xu, Ning
    Huang, Xiaoping
    Dong, Xiaoting
    Zhou, Zhonghui
    Yu, Yali
    Shangguan, Zongxiao
    Xu, Yangyang
    Ying, Weiping
    Weng, Meiling
    Yuan, Zuguo
    Dong, Zhijun
    Li, Jifa
    Zheng, Zhe
    Pan, Jiongwei
    Liu, Lu
    Ye, Junhui
    Zhang, Zhan
    Li, Wenfeng
    Zhu, Junfei
    Jin, Shengnan
    Li, Yuping
    Ding, Chunming
    TARGETED ONCOLOGY, 2019, 14 (06) : 719 - 728
  • [25] Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
    Passaro, Antonio
    Guerini-Rocco, Elena
    Pochesci, Alessia
    Vacirca, Davide
    Spitaleri, Gianluca
    Catania, Chiara Matilde
    Rappa, Alessandra
    Barberis, Massimo
    de Marinis, Filippo
    PHARMACOLOGICAL RESEARCH, 2017, 117 : 406 - 415
  • [26] EGFR T790M Detection Differences by Original Mutation Types and Detection Samples
    Wang, C.
    Wu, W.
    Xiong, M.
    Wu, C.
    Ni, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S441 - S441
  • [27] Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
    Matsuda, Asako
    Fuchimoto, Yasuko
    Wada, Sae
    Tanaka, Takaaki
    Takeguchi, Tetsuya
    Mitsumune, Sho
    Takigawa, Yuki
    Miyamoto, Yosuke
    Ozaki, Shinji
    Iga, Norichika
    Nishi, Hideyuki
    Fujimoto, Nobukazu
    CASE REPORTS IN ONCOLOGY, 2019, 12 (03): : 918 - 921
  • [28] The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
    Godin-Heymann, Nadia
    LlIkus, Lindsey
    Brannigan, Brian W.
    McDermott, Ultan
    Lamb, Jennifer
    Maheswaran, Shyamala
    Settleman, Jeffrey
    Haber, Daniel A.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (04) : 874 - 879
  • [29] Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
    Sagan, Olivia A.
    Rothstein, Anna
    Jambunathan, Bhaghyasree
    Hadziahmetovic, Mersiha
    Antoniolli, Anita
    Rashid, M. Hammad
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] SPHEROID STUDY OF A GLIOBLASTOMA TUMOR IDENTIFIED A SUBCLONAL MUTATION OF EGFR T790M
    Rosenberg, Shai
    Steinberg, Eliana
    Yaacov, Adar
    Lutati, Ranel
    Mordechai, Anat
    Linetsky, Eduard
    Lossos, Alexander
    Paldor, Ido
    Benny, Ofra
    NEURO-ONCOLOGY, 2020, 22 : 75 - 75